brigatinib and its Impurities

Brigatinib acts as both an anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor. It is a small molecule targeted cancer therapy being developed by ARIAD Pharmaceuticals, Inc.. Reference standards of Brigatinib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below

Displaying 2 results for brigatinib Impurities
PA 29 44000

Brigatinib

Brigatinib

  • Catalogue No.:PA 29 44000

  • CAS :

    1197953-54-0

  • Molecular Formula : C29H39ClN7O2P

  • Molecular Weight : 584.09

Enquire
Details
PA 29 0441000

2,4-Pyrimidinediamine, 5-chloro-N4-[2-(dimethylphosphinyl)phenyl]-N2-[2-methoxy-4-[4-(1-piperazinyl)-1-piperidinyl]phenyl]

2,4-Pyrimidinediamine, 5-chloro-N4-[2-(dimethylphosphinyl)phenyl]-N2-[2-methoxy-4-[4-(1-piperazinyl)-1-piperidinyl]phenyl]

  • Catalogue No.:PA 29 0441000

  • CAS :

    1197958-75-0

  • Molecular Formula : C28H37ClN7O2P

  • Molecular Weight : 570.07

Enquire
Details
Tools

Calculators

Normality Dilution Mass molarity
Periodic Table- Pharmaffiliates

Periodic Table

Ask A Scientist-Pharmaffiliates

Ask a Scientist
General Help

General Help
CPHI INDIA- 28, 30 November